Multiple Myeloma Diagnostics Market

Multiple Myeloma Diagnostics Market: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019 - 2029

Market Overview

Multiple Myeloma Diagnostics: Market Insights

Plasma cells help in fighting infection however, malignant plasma cells in multiple myeloma accumulate in the bone marrow, blocks the normal function of plasma cells. The M protein which is an abnormal antibody produced by malignant plasma cells cause tumors, bone destruction, kidney damage, and damaged immune function. However, in the recent years, ten new drugs have received in approval in short period of time due to the formation of Multiple Myeloma Research Foundation and the increasing attention, advancement, and researches for multiple myeloma diagnostics and therapies. These factors contributing to the growth of multiple myeloma diagnostics market. Moreover, increasing funding for the research and development and rising clinical trials is expected to provide the most promising multiple myeloma treatments options and will boost the growth of multiple myeloma diagnostics market.

Multiple Myeloma Diagnostics: Market Insights

Plasma cells help in fighting infection however, malignant plasma cells in multiple myeloma accumulate in the bone marrow, blocks the normal function of plasma cells. The M protein which is an abnormal antibody produced by malignant plasma cells cause tumors, bone destruction, kidney damage, and damaged immune function. However, in the recent years, ten new drugs have received in approval in short period of time due to the formation of Multiple Myeloma Research Foundation and the increasing attention, advancement, and researches for multiple myeloma diagnostics and therapies. These factors contributing to the growth of multiple myeloma diagnostics market. Moreover, increasing funding for the research and development and rising clinical trials is expected to provide the most promising multiple myeloma treatments options and will boost the growth of multiple myeloma diagnostics market.

Multiple Myeloma Diagnostics: Overview

Technological advancement and rising clinical studies for the management of multiple myeloma are the main factor to boost the market growth of multiple myeloma diagnostics market. Additionally, rising disposable income is expected to boost the growth of multiple myeloma diagnostics market. However, lack of awareness and expertise can lead to complications and can damaged the immune function of the heart which may lead to the heart failure. The poor management of multiple myeloma may lead to restraint the growth of multiple myeloma diagnostics market.

Multiple Myeloma Diagnostics: Region-wise Outlook

The Asia-Pacific multiple myeloma diagnostics market is expected to show fast growth due to rising heart-related problems and lack of awareness regarding the management of multiple myeloma. The multiple myeloma diagnostics market is expected to be dominated by North America due to advanced healthcare infrastructure and reimbursement in the region. Latin America Multiple myeloma diagnostics market is expected to experience steady growth due to lack of expertise in the region. Europe is expected to score second place in the multiple myeloma diagnostics market due to availability of skilled healthcare professionals coupled with higher adoption in the region. The Middle East & Africa is expected to be the least lucrative multiple myeloma diagnostics market due to least product availability and lack of facilities in the region.

Multiple Myeloma Diagnostics: Key Players

Some of the key players present in global multiple myeloma diagnostics market are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genzyme Corporation, Celgene Corporation, Millennium Pharmaceuticals, Novartis AG, Amgen, Inc., Juno Therapeutics, Janssen Biotech, Inc., Johnson & Johnson, GlaxoSmithKline plc, Pfizer, AbbVie Inc., Innate Pharma SA, Onyx Pharmaceuticals, Celldex Therapeutics, Inc., and Takeda Pharmaceuticals.

The report covers exhaustive analysis on:

  • Multiple Myeloma Diagnostics Market Segments
  • Multiple Myeloma Diagnostics Market Dynamics
  • Multiple Myeloma Diagnostics Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Multiple Myeloma Diagnostics Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Russia, Rest of Europe)
  • East Asia (China, Japan, South Korea)
  • South Asia (India, Indonesia, Malaysia, Rest of East Asia)
  • Middle East and Africa (N. Africa, S. Africa, Israel, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Multiple Myeloma Diagnostics: Segmentation

The global Multiple Myeloma Diagnostics market is segmented by drug type, end user, and regions:

Multiple Myeloma Diagnostics Segmentation by Drug Type

  • Proteasome Inhibitors
  • Velcade (bortezomib)
  • Kyprolis® (carfilzomib)
  • Ninlaro® (ixazomib)
  • Immunomodulatory Agents (IMiDs)
  • Thalomid® (thalidomide)
  • Revlimid® (lenalidomide)
  • Pomalyst® (pomalidomide)
  • Histone Deacetylase (HDAC) inhibitors
  • Farydak® (panobinostat)
  • Immunotherapy
  • Darzalex™ (daratumumab)
  • Empliciti® (elotuzumab)
  • Cytotoxic Chemotherapy
  • Doxil

Multiple Myeloma Diagnostics Segmentation by Distribution Channel

  • Institutional Sales
  • Hospital Pharmacies
  • Specialty Clinic
  • Retail Sales
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Multiple Myeloma Diagnostics Market